Latest Medivir News & Updates

See the latest news and media coverage for Medivir. We track all announcements, press releases, and industry mentions in real time, all in one place.

Medivir

Oncology drug discovery and development company

medivir.com

Headquarters: Huddinge, Sweden
Founded year: 1988
Company type: Public company
Number of employees: 2–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Medivir

In short: Medivir advanced its oncology pipeline, secured significant funding through share issues, and strengthened its US patent portfolio.

Company announcements

July 20 Medivir

Medivir's EGM approves directed share issue

The resolution was part of a two-tranche process initiated in June 2026. Up to 6,097,560 new shares to Hallberg Management AB were approved.

July 20 Medivir

Medivir receives Notice of Allowance for combination patent in USA

The patent covers fostrox plus lenvatinib for liver cancer treatment. It provides exclusivity until 2041.

June 30 Medivir

Medivir announces change in shares and votes

The share issue increased shares by 79 million, with votes totaling 618 million.

June 22 Medivir

Medivir publishes disclosure document for share admission to Nasdaq Stockholm

The document relates to a directed share issue of 85,365,854 new shares to institutional investors.

Media coverage

Yesterday The Globe and Mail

Medivir Expands Share Capital to Fund MIV-711 Orphan Indication

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

July 19 FinanzNachrichten.de

Medivir AB: Medivir receives Notice of Allowance for fostrox plus lenvatinib combination patent in the USA

Stockholm - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces today that...

June 17 Dagens Juridik

Lindahl advisor to Medivir in directed share issue of approximately SEK 140 million - Dagens Juridik

Law firm Lindahl has acted as legal advisor to Medivir AB (publ) in connection with a directed share issue of approximately SEK 140 million to Swedish and international institutional...

June 9 The Globe and Mail

Medivir’s fostrox combo shows promising liver cancer data in key journal

Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment ...

Never miss news about Medivir

Track Medivir and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Medivir competitors & trending companies

Browse news for competitors to Medivir and other trending companies.